MEM
MEMPHASYS LIMITED.
$0.0050
0.00%
Market cap
$15M
Turnover
$780
Last price
$0.0050
Day change
0.00%
Announcements
19
Range, past year
Open 0.004 · Low 0.003 · Now 0.005 · High 0.009
Open MEM in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
MEM momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
20/100
Wyckoff phase
Accumulation9d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+0.0%
1 Month
-16.7%
1 Year
+25.0%
RSI
43
Avg daily range
11.2%
MEMPHASYS LIMITED. scores 20 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 9 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -37.5%
- High volatility (ATR 11.2%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
MEM announcements
Recent price-sensitive releases.
- 2026-10-13 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-09-29 Memphasys receives A$3.5 million from Peters Investments Capital Reconstruction | Notice of Meeting - Other | Progress Report | Debt Facility
- 2026-09-25 Potential Expedited FDA Pathway to US IVF Market Progress Report
- 2026-09-18 Memphasys Secures European Felix Agreement Progress Report
- 2026-09-03 Felix Registration Achieved in Turkey, Sales Commence Progress Report
- 2026-09-01 EUR526,500 Nordic Agreement Expands Felix European Footprint Progress Report
- 2026-08-31 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
More Health Care stocks
Most traded in the same sector.